Generation Bio(US:GBIO)2025-08-12 20:10Financial Performance - Generation Bio reported a net loss of $20.9 million, or $3.12 per share, for Q2 2025, compared to a net loss of $20.4 million, or $3.07 per share, in Q2 2024[17]. - Cash, cash equivalents, and marketable securities decreased to $141.4 million as of June 30, 2025, down from $185.2 million as of December 31, 2024[11]. - Total operating expenses for Q2 2025 were $23.7 million, down from $27.4 million in Q2 2024[23]. Research and Development - Research and development expenses for Q2 2025 were $15.5 million, a decrease from $16.4 million in Q2 2024[11]. - The company achieved significant knockdown of beta-2 microglobulin in T cells using a 0.5 mg/kg dose of ctLNP-siRNA in a non-human primate study[5]. - Generation Bio's lead siRNA candidates demonstrated potent knockdown of LAT1 and VAV1, which are relevant to T cell-driven autoimmune diseases[7]. Strategic Initiatives - The company is exploring strategic alternatives, including potential acquisitions or mergers, to maximize shareholder value[9]. - A recent litigation settlement will extinguish a lease liability of $58 million, with a lump sum payment of $31 million to the landlord[17]. - The company anticipates a workforce reduction of approximately 90% as part of a strategic restructuring process[10]. Operating Expenses - General and administrative expenses were $7.7 million for Q2 2025, down from $9.5 million in Q2 2024[11].